Form 4: Aptevo Therapeutics Inc. Executive Daphne Taylor Reports Acquisition of Restricted Stock Units

Daphne Taylor, SVP and CFO of Aptevo Therapeutics Inc., reports the acquisition of 8,550 Restricted Stock Units (RSUs) that will vest in common stock over three years.

Summary

• On July 17, 2024, Daphne Taylor, SVP and CFO of Aptevo Therapeutics Inc., acquired 8,550 Restricted Stock Units (RSUs).
• These RSUs convert into common stock of Aptevo Therapeutics Inc. on a one-for-one basis.
• The RSUs vest in three approximately equal annual installments beginning on July 17, 2025.
• Following the transaction, Ms. Taylor directly owns 8,550 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of RSUs by an executive is generally viewed as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of RSUs by a key executive may indicate confidence in the company's future performance.

Future Outlook

The RSUs will vest over the next three years, potentially increasing Ms. Taylor's stake in the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment as it reflects insider confidence.

Key Dates

Keywords

Aptevo Therapeutics Inc., Daphne Taylor, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership, SVP, CFO, Equity Securities